대한약품

023910KOSDAQ의약품 제조업

59.5 / 100

Reference Date: 2026-06-10

Financial Score32.0 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Declined 7.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Daehan Pharmaceuticals primarily produces and sells essential pharmaceuticals such as intravenous solutions, ampoules, and OTC products like lens cleaning solutions. In 2024, the company achieved revenue of 204.1 billion won and operating profit of 38 billion won. Through investments in new production lines and automated warehouses, the company has enhanced its large-scale manufacturing and quality control capabilities, maintaining over 80% of sales in hospitals and pharmacies domestically.

Number of Employees

737people

Average Salary

61.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.59Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR

0.53Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

9.60Industry Average 4.017.0Point

2.4x industry avg (excellent)

Debt Ratio

1.31Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼5.9% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 26,300Won52-week high 33,70052-week low 26,050

1-month return1.0Point

1m -7.56% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-28
Neutral주식등의대량보유상황보고서(일반)2026-05-28
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-22
Neutral분기보고서 (2026.03)2026-05-15